PARP1 and triple-negative breast carcinoma: A dual PARP and RAD51 inhibitor might as well re-sensitize triple-negative breast cancer (TNBC) cells with hereditary and acquired defects in the BRCA1 pathway [17] after development of PARP inhibitor resistance reconstituting the HR machinery [18].